阅读说明：本技术 Wt1多肽肿瘤抑制剂 (WT1 polypeptide tumor inhibitor ) 是由 李坤鹏 于 2020-07-01 设计创作，主要内容包括：本发明公开了提供一种由9条来自于WT1蛋白序列的多肽组成的抗原。该抗原是通过计算机软件对WT1靶点进行了分析,将该蛋白抗原性最好的一部分进行序列拆分,组合成为9条长肽做为抗原序列。本发明的多肽组合具有抗肿瘤效果更好,谱系更广的优点。(The invention discloses an antigen consisting of 9 polypeptides from WT1 protein sequences. The antigen is obtained by analyzing WT1 target spot with computer software, and separating the sequence of the part with the best antigenicity of the protein to combine 9 long peptides as antigen sequence. The polypeptide combination has the advantages of better anti-tumor effect and wider pedigree.)

1. A WT1 polypeptide tumor suppressor comprising 9 polypeptides of the following sequence:

>1

SNPARYEFLMHSRKHTGEKPYQCDFKDCERRFSRSDQLKVLEHVVRVNARVRI

>2

LSNPARYEFLKRHQRRHTGVKPFQCKTCQVLEHVVRVNARVRIRKF

>3

LSNPARYEFLKRHQRRHTGVKPFVLEHVVRVNARVRIQCK

>4

HSNPARYEFLTRTHTGKTSEKPFSVLEHVVRVNARVRICRW

>5

TSEKPFSCRVLEHVVRVNARVRI

>6

CRWPSCQKKVLEHVVRVNARVRI

>7

QKKFARSDEVLEHVVRVNARVRI

>8

SDELVRHHNVLEHVVRVNARVRI

>9

HHNMHQRNMVLEHVVRVNARVRI。

2. the WT1 polypeptide tumor suppressor of claim 1, which further comprises other adjuvants.

3. The method for preparing the WT1 polypeptide tumor suppressor of claim 1 or 2.

4. The use of the WT1 polypeptide tumor suppressor of claim 1 or 2 for the preparation of an anti-tumor medicament.

5. The use of claim 4, wherein the tumor is a rectal cancer, a colon cancer, a liver cancer, a breast cancer.

6. The use of claim 4, wherein the neoplasm is cervical cancer.

Technical Field

The invention relates to the field of tumor treatment, in particular to a WT1 polypeptide tumor inhibitor.

Background

The key to active specific immunotherapy of malignancies is the selection of appropriate antigenic targets, and the 2009 National Cancer Institute (NCI) analysis contrasts 75 malignant tumor antigens, with the eventual development that renal cell tumor1 (nephrobastoma or Wilm's tumor1, WT1) is the best malignant tumor antigen.

The preparation method of the polypeptide antigen is simple, but the mechanism for playing the anticancer role is very complex, and the cancer cell can be eliminated only by presenting the polypeptide antigen to a T cell through a DC cell after entering a body. According to research, the single polypeptide and short peptide antigen (less than 35 amino acids) adopted internationally at present cannot completely cover all patients to produce better curative effect. And the indications developed internationally aiming at the target point at present mainly focus on hemangioma and myeloma. The target drug aiming at other solid tumors is yet to be developed.

The invention aims to provide an antigen consisting of 9 polypeptides derived from WT1 protein sequences. The antigen is obtained by analyzing WT1 target spot with computer software, and separating the sequence of the part with the best antigenicity of the protein to combine 9 long peptides as antigen sequence.

Disclosure of Invention

The invention aims to provide an antigen consisting of 9 polypeptides derived from a WT1 protein sequence.

A WT1 polypeptide tumor suppressor comprising 9 polypeptides of the following sequence:

the invention has the advantages that:

the invention aims to provide an antigen consisting of 9 polypeptides derived from WT1 protein sequences. The antigen is obtained by analyzing WT1 target spot with computer software, and separating the sequence of the part with the best antigenicity of the protein to combine 9 long peptides as antigen sequence. The single polypeptide and short peptide antigen (less than 35 amino acids) adopted internationally at present can not completely cover all patients to generate better curative effect, and are mainly concentrated on hemangioma and myeloma. In addition, the 9 short peptide compositions have good in-vitro inhibition effect, and can further increase the application treatment range.

Drawings

FIG. 1 shows the antigenicity analysis of WT 1.

FIG. 2 shows epitope analysis of WT 1.

FIG. 3 is a graph showing the pharmacodynamic analysis of WT1 on breast cancer.

FIG. 4 is a graph of WT1 ramp test for breast cancer.

FIG. 5 is a graph showing a climbing test of WT1 on colon cancer.

Detailed Description

The following examples of the present invention are described in detail, and are only for the purpose of illustrating the present invention and are not to be construed as limiting the present invention.

Specific examples of the present invention are described below.

The animal experiment consigns the Guangzhou Jinie Europe organism to carry out synthesis and the protein antigen consigns the Nanjing Minggao organism to carry out synthesis.